HomeInsightsStock Comparison

Accretion Pharmaceuticals Ltd vs Wanbury Ltd Stock Comparison

Accretion Pharmaceuticals Ltd vs Wanbury Ltd Stock Comparison

Last Updated on: May 29, 2025

Key Highlights

  • The Latest Trading Price of Accretion Pharmaceuticals Ltd is ₹ 68 as of 29 May 13:19.
  • The P/E Ratio of Accretion Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Wanbury Ltd changed from 0.7 on March 2020 to 8.5 on March 2024 . This represents a CAGR of 64.76% over 5 years.
  • The Market Cap of Accretion Pharmaceuticals Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Wanbury Ltd changed from ₹ 45.49 crore on March 2020 to ₹ 477.59 crore on March 2024 . This represents a CAGR of 60.04% over 5 years.
  • The revenue of Accretion Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Wanbury Ltd for the Mar '25 is ₹ 173.84 crore as compare to the Dec '24 revenue of ₹ 134.29 crore. This represent the growth of 29.45%.
  • The ebitda of Accretion Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Wanbury Ltd for the Mar '25 is ₹ 31.47 crore as compare to the Dec '24 ebitda of ₹ 14.78 crore. This represent the growth of 112.92%.
  • The net profit of Accretion Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Wanbury Ltd changed from ₹ 4.69 crore to ₹ 20.26 crore over 8 quarters. This represents a CAGR of 107.84% .
  • The Dividend Payout of Accretion Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Wanbury Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Accretion Pharmaceuticals Ltd

  • Accretion Pharmaceuticals was incorporated in year 2012, the Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, to provide health care products.
  • Thus, the foundation of 'Accretion Pharmaceuticals' was laid down, which was started as a Partnership Firm in the name of 'M/s Accretion Pharmaceuticals', pursuant to a deed of partnership dated December 18, 2012. The manufacturing facility which is currently located at Ahmedabad, in Sanand District of Gujarat, commenced its manufacturing operations in year 2014.
  • Thereafter, the Partnership Firm was converted into a Limited Company in the name of 'Accretion Pharmaceuticals Limited' and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

About Wanbury Ltd

  • Wanbury Ltd (Formerly known Pearl Organics Limited) was incorporated in August, 1988.
  • The Company is engaged in the business of pharmaceutical and related activities, including research. The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs.
  • In 1995, the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga.
  • In 1996, it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US. In 2007-08, the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April, 2007.
  • Pursuant to the aforesaid Order of the Hon'ble Bl FR 7,85,557 Equity Shares of face value of Rs. 10/- each of the Company were issued to the Equity Shareholders of DOCL on 17th March, 2008.

Accretion Pharmaceuticals Ltd News Hub

News

NSE SME Accretion Pharma stumbles on market debut

The scrip was listed at 79, a discount of 21.78% over the initial public offer (IPO) price...

Read more

21 May 2025 10:38

News

NSE SME Accretion Pharmaceuticals' IPO ends with subscription of 7.31 times

The initial public offer (IPO) of Accretion Pharmaceuticals received bids for 2,00,06,400 ...

Read more

19 May 2025 11:43

Wanbury Ltd News Hub

News

Wanbury's Patalganga facility receives GMP certification from ANVISA

Earlier this month, on 12 May 2025, the company had also received GMP approval from ANVISA...

Read more

20 May 2025 10:09

News

Wanbury spurts after Tanuku facility clears ANVISA inspection with zero observations

The inspection was conducted from 16 December to 20 December 2024, confirmed the facility'...

Read more

12 May 2025 15:25

News

Wanbury announces board meeting date

Wanbury will hold a meeting of the Board of Directors of the Company on 15 May 2025. Power...

Read more

09 May 2025 10:33

News

Wanbury edges higher post conclusion of NCD refinancing at lower rates

The company stated that it has repurchased the entire Rs 95 crore issue of 21% secured NCD...

Read more

06 Mar 2025 12:11

News

Wanbury to declare Quarterly Results

Wanbury will hold a meeting of the Board of Directors of the Company on 12 February 2025. ...

Read more

11 Feb 2025 10:53

News

Wanbury to conduct EGM

Wanbury announced that an Extra Ordinary General Meeting (EGM) of the Company will be held...

Read more

09 Jan 2025 10:32

SWOT Analysis Of Wanbury Ltd

Strength

1

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Wanbury Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of null and Wanbury Ltd

Which company has a larger market capitalization, Accretion Pharmaceuticals Ltd or Wanbury Ltd?

Market cap of Accretion Pharmaceuticals Ltd is 77 Cr while Market cap of Wanbury Ltd is 914 Cr

What are the key factors driving the stock performance of Accretion Pharmaceuticals Ltd and Wanbury Ltd?

The stock performance of Accretion Pharmaceuticals Ltd and Wanbury Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Pharmaceuticals Ltd and Wanbury Ltd?

As of May 29, 2025, the Accretion Pharmaceuticals Ltd stock price is INR ₹69.9. On the other hand, Wanbury Ltd stock price is INR ₹279.0.

How do dividend payouts of Accretion Pharmaceuticals Ltd and Wanbury Ltd compare?

To compare the dividend payouts of Accretion Pharmaceuticals Ltd and Wanbury Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions